Tocilizumab in patients with severe COVID-19 : A single-center observational analysis
© 2020 Wiley Periodicals LLC..
Patients with coronavirus disease 2019 (COVID-19) may develop severe respiratory distress, thought to be mediated by cytokine release. Elevated proinflammatory markers have been associated with disease severity. Tocilizumab, an interleukin-6 receptor antagonist, may be beneficial for severe COVID-19, when cytokine storm is suspected. This is a retrospective single-center analysis of the records of patients diagnosed with COVID-19 who received tocilizumab. Outcomes, including clinical improvement, mortality and changes in oxygen-support at 24, 48, and 72 hours, and 7, 14, and 28 days post-tocilizumab, are reported. Patients were evaluated by baseline pre-tocilizumab oxygenation status and changes in proinflammatory markers within 7 days post-tocilizumab are reported. Sixty-six patients received tocilizumab at a mean dose of 724 mg (7.4 mg/kg), 3.7 days from admission. At baseline, 53% of patients were on ventilation support and all had elevated proinflammatory markers, including c-reactive protein (CRP). Common comorbidities were diabetes mellitus (43%) and hypertension (74%). Most patients received concomitant glucocorticoids and hydroxychloroquine. Seven days after tocilizumab, ten patients (15.2%) had clinical improvement in their oxygenation status, and there was a 95% decrease in CRP. Within 14 days of treatment, 29% of patients had clinical improvement, 20% had minimal or no improvement, 17% worsened, 27% died, and 7% were transferred to an outside hospital. Ultimately, 42% of all patients that received tocilizumab expired and 49% were discharged. This study found limited clinical improvement in patients that received tocilizumab in the setting of severe COVID-19. Clinical trials are ongoing to further evaluate tocilizumab's benefit in this patient population.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2020 |
---|---|
Erschienen: |
2020 |
Enthalten in: |
Zur Gesamtaufnahme - volume:92 |
---|---|
Enthalten in: |
Journal of medical virology - 92(2020), 11 vom: 25. Nov., Seite 2813-2820 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Knorr, John P [VerfasserIn] |
---|
Links: |
---|
Anmerkungen: |
Date Completed 31.12.2020 Date Revised 07.12.2022 published: Print-Electronic Citation Status MEDLINE |
---|
doi: |
10.1002/jmv.26191 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM312056990 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM312056990 | ||
003 | DE-627 | ||
005 | 20231225143608.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2020 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1002/jmv.26191 |2 doi | |
028 | 5 | 2 | |a pubmed24n1040.xml |
035 | |a (DE-627)NLM312056990 | ||
035 | |a (NLM)32628003 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Knorr, John P |e verfasserin |4 aut | |
245 | 1 | 0 | |a Tocilizumab in patients with severe COVID-19 |b A single-center observational analysis |
264 | 1 | |c 2020 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 31.12.2020 | ||
500 | |a Date Revised 07.12.2022 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a © 2020 Wiley Periodicals LLC. | ||
520 | |a Patients with coronavirus disease 2019 (COVID-19) may develop severe respiratory distress, thought to be mediated by cytokine release. Elevated proinflammatory markers have been associated with disease severity. Tocilizumab, an interleukin-6 receptor antagonist, may be beneficial for severe COVID-19, when cytokine storm is suspected. This is a retrospective single-center analysis of the records of patients diagnosed with COVID-19 who received tocilizumab. Outcomes, including clinical improvement, mortality and changes in oxygen-support at 24, 48, and 72 hours, and 7, 14, and 28 days post-tocilizumab, are reported. Patients were evaluated by baseline pre-tocilizumab oxygenation status and changes in proinflammatory markers within 7 days post-tocilizumab are reported. Sixty-six patients received tocilizumab at a mean dose of 724 mg (7.4 mg/kg), 3.7 days from admission. At baseline, 53% of patients were on ventilation support and all had elevated proinflammatory markers, including c-reactive protein (CRP). Common comorbidities were diabetes mellitus (43%) and hypertension (74%). Most patients received concomitant glucocorticoids and hydroxychloroquine. Seven days after tocilizumab, ten patients (15.2%) had clinical improvement in their oxygenation status, and there was a 95% decrease in CRP. Within 14 days of treatment, 29% of patients had clinical improvement, 20% had minimal or no improvement, 17% worsened, 27% died, and 7% were transferred to an outside hospital. Ultimately, 42% of all patients that received tocilizumab expired and 49% were discharged. This study found limited clinical improvement in patients that received tocilizumab in the setting of severe COVID-19. Clinical trials are ongoing to further evaluate tocilizumab's benefit in this patient population | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Observational Study | |
650 | 4 | |a COVID-19 | |
650 | 4 | |a IL-6 antagonist | |
650 | 4 | |a cytokine release syndrome | |
650 | 4 | |a cytokine storm | |
650 | 4 | |a tocilizumab | |
650 | 7 | |a Antibodies, Monoclonal, Humanized |2 NLM | |
650 | 7 | |a Fibrin Fibrinogen Degradation Products |2 NLM | |
650 | 7 | |a Receptors, Interleukin-6 |2 NLM | |
650 | 7 | |a fibrin fragment D |2 NLM | |
650 | 7 | |a C-Reactive Protein |2 NLM | |
650 | 7 | |a 9007-41-4 |2 NLM | |
650 | 7 | |a Ferritins |2 NLM | |
650 | 7 | |a 9007-73-2 |2 NLM | |
650 | 7 | |a L-Lactate Dehydrogenase |2 NLM | |
650 | 7 | |a EC 1.1.1.27 |2 NLM | |
650 | 7 | |a tocilizumab |2 NLM | |
650 | 7 | |a I031V2H011 |2 NLM | |
650 | 7 | |a Oxygen |2 NLM | |
650 | 7 | |a S88TT14065 |2 NLM | |
700 | 1 | |a Colomy, Veronika |e verfasserin |4 aut | |
700 | 1 | |a Mauriello, Christine M |e verfasserin |4 aut | |
700 | 1 | |a Ha, Seung |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Journal of medical virology |d 1990 |g 92(2020), 11 vom: 25. Nov., Seite 2813-2820 |w (DE-627)NLM000285676 |x 1096-9071 |7 nnns |
773 | 1 | 8 | |g volume:92 |g year:2020 |g number:11 |g day:25 |g month:11 |g pages:2813-2820 |
856 | 4 | 0 | |u http://dx.doi.org/10.1002/jmv.26191 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 92 |j 2020 |e 11 |b 25 |c 11 |h 2813-2820 |